ER+/HER2+ breast cancer: are we really de-escalating? | Ann Oncol;30(6): 875-877, 2019 06 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL CLAP/WR-PAHO/WHO

Latin-American Center for Perinatology, Woman and Reproductive Health

Subject descriptor lookup Advanced Search

ER+/HER2+ breast cancer: are we really de-escalating?

de Azambuja, E; Piccart-Gebhart, M.

Affiliation

de Azambuja E; Department of Medical Oncology, Institut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium. Electronic address: evandro.azambuja@bordet.be.
Piccart-Gebhart M; Department of Medicine, Institut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium.

Ann Oncol ; 30(6): 875-877, 2019 06 01.

Article in En | MEDLINE | ID: mdl-30993330

Subject(s)

Breast Neoplasms; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Receptor, ErbB-2

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Type: Article

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Type: Article